OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
Lampros Chrysavgis, Alkistis‐Maria Papatheodoridi, Antonios Chatzigeorgiou, et al.
Journal of Gastroenterology and Hepatology (2020) Vol. 36, Iss. 4, pp. 893-909
Open Access | Times Cited: 24
Lampros Chrysavgis, Alkistis‐Maria Papatheodoridi, Antonios Chatzigeorgiou, et al.
Journal of Gastroenterology and Hepatology (2020) Vol. 36, Iss. 4, pp. 893-909
Open Access | Times Cited: 24
Showing 24 citing articles:
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Θεόδωρος Ανδρουτσάκος, Narjes Nasiri‐Ansari, Athanasios‐Dimitrios Bakasis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3107-3107
Open Access | Times Cited: 98
Θεόδωρος Ανδρουτσάκος, Narjes Nasiri‐Ansari, Athanasios‐Dimitrios Bakasis, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3107-3107
Open Access | Times Cited: 98
Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis
Chloe Wong, Clyve Yu Leon Yaow, Cheng Han Ng, et al.
Frontiers in Endocrinology (2021) Vol. 11
Open Access | Times Cited: 51
Chloe Wong, Clyve Yu Leon Yaow, Cheng Han Ng, et al.
Frontiers in Endocrinology (2021) Vol. 11
Open Access | Times Cited: 51
European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
Stephan C. Bischoff, Rocco Barazzoni, Luca Busetto, et al.
Clinical Nutrition (2022) Vol. 41, Iss. 10, pp. 2364-2405
Open Access | Times Cited: 38
Stephan C. Bischoff, Rocco Barazzoni, Luca Busetto, et al.
Clinical Nutrition (2022) Vol. 41, Iss. 10, pp. 2364-2405
Open Access | Times Cited: 38
European guideline on obesity care in patients with gastrointestinal and liver diseases – Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline
Stephan C. Bischoff, Rocco Barazzoni, Luca Busetto, et al.
United European Gastroenterology Journal (2022) Vol. 10, Iss. 7, pp. 663-720
Open Access | Times Cited: 38
Stephan C. Bischoff, Rocco Barazzoni, Luca Busetto, et al.
United European Gastroenterology Journal (2022) Vol. 10, Iss. 7, pp. 663-720
Open Access | Times Cited: 38
The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, et al.
Pharmacological Research (2022) Vol. 181, pp. 106261-106261
Closed Access | Times Cited: 25
Konstantinos Arvanitakis, Theocharis Koufakis, Kalliopi Kotsa, et al.
Pharmacological Research (2022) Vol. 181, pp. 106261-106261
Closed Access | Times Cited: 25
Practical guideline on obesity care in patients with gastrointestinal and liver diseases – Joint ESPEN/UEG guideline
Stephan C. Bischoff, Johann Ockenga, Ahad Eshraghian, et al.
Clinical Nutrition (2023) Vol. 42, Iss. 6, pp. 987-1024
Open Access | Times Cited: 16
Stephan C. Bischoff, Johann Ockenga, Ahad Eshraghian, et al.
Clinical Nutrition (2023) Vol. 42, Iss. 6, pp. 987-1024
Open Access | Times Cited: 16
Current and emerging strategies for the prevention of hepatocellular carcinoma
Yee Hui Yeo, Manal F. Abdelmalek, Seema A. Khan, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 22, Iss. 3, pp. 173-190
Closed Access | Times Cited: 4
Yee Hui Yeo, Manal F. Abdelmalek, Seema A. Khan, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 22, Iss. 3, pp. 173-190
Closed Access | Times Cited: 4
Unlocking the therapeutic potential of canagliflozin in NAFLD: Insights into AMPK/SIRT1-mediated lipophagy
Nahla E. El‐Ashmawy, Ghada M. Al‐Ashmawy, Asmaa A. Kamel, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 3, pp. 167666-167666
Closed Access
Nahla E. El‐Ashmawy, Ghada M. Al‐Ashmawy, Asmaa A. Kamel, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025) Vol. 1871, Iss. 3, pp. 167666-167666
Closed Access
Sodium-Glucose Cotransporter2 inhibitors and associated Liver-Related outcomes in diabetes patients
Fu‐Shun Yen, James Cheng‐Chung Wei, Congrong Wang, et al.
Diabetes Research and Clinical Practice (2025) Vol. 223, pp. 112174-112174
Closed Access
Fu‐Shun Yen, James Cheng‐Chung Wei, Congrong Wang, et al.
Diabetes Research and Clinical Practice (2025) Vol. 223, pp. 112174-112174
Closed Access
Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease
Angeliki Katsarou, Georgios Tsioulos, Eva Kassi, et al.
HORMONES (2024) Vol. 23, Iss. 4, pp. 621-636
Closed Access | Times Cited: 3
Angeliki Katsarou, Georgios Tsioulos, Eva Kassi, et al.
HORMONES (2024) Vol. 23, Iss. 4, pp. 621-636
Closed Access | Times Cited: 3
A personalized approach to the treatment of patients with chronic heart failure with preserved ejection fraction and non-alcoholic fatty liver disease using dapagliflozin
О. В. Цыганкова, О. В. Тимощенко, Л. Д. Латынцева, et al.
Experimental and Clinical Gastroenterology (2025), Iss. 9, pp. 14-25
Closed Access
О. В. Цыганкова, О. В. Тимощенко, Л. Д. Латынцева, et al.
Experimental and Clinical Gastroenterology (2025), Iss. 9, pp. 14-25
Closed Access
Metabolic-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes: Mechanisms, Diagnostic Approaches, and Therapeutic Interventions
Anastasia Ntikoudi, A Papachristou, Afroditi Tsalkitzi, et al.
Diabetology (2025) Vol. 6, Iss. 4, pp. 23-23
Open Access
Anastasia Ntikoudi, A Papachristou, Afroditi Tsalkitzi, et al.
Diabetology (2025) Vol. 6, Iss. 4, pp. 23-23
Open Access
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts
Cristina Rebordosa, Reimar W. Thomsen, Arlene Tave, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 4, pp. 1291-1304
Open Access | Times Cited: 2
Cristina Rebordosa, Reimar W. Thomsen, Arlene Tave, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 4, pp. 1291-1304
Open Access | Times Cited: 2
Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2
Kei Yoshino, Tetsuya Hosooka, Masakazu Shinohara, et al.
Biochemical and Biophysical Research Communications (2021) Vol. 557, pp. 62-68
Open Access | Times Cited: 13
Kei Yoshino, Tetsuya Hosooka, Masakazu Shinohara, et al.
Biochemical and Biophysical Research Communications (2021) Vol. 557, pp. 62-68
Open Access | Times Cited: 13
Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
Gea Ciccarelli, Gianfranco Di Giuseppe, Francesca Cinti, et al.
Diabetes/Metabolism Research and Reviews (2023) Vol. 39, Iss. 7
Open Access | Times Cited: 5
Gea Ciccarelli, Gianfranco Di Giuseppe, Francesca Cinti, et al.
Diabetes/Metabolism Research and Reviews (2023) Vol. 39, Iss. 7
Open Access | Times Cited: 5
Increased PRL-1 in BM-derived MSCs triggers anaerobic metabolism via mitochondria in a cholestatic rat model
Jae Yeon Kim, Se Ho Kim, Jin Seok, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 31, pp. 512-524
Open Access | Times Cited: 4
Jae Yeon Kim, Se Ho Kim, Jin Seok, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 31, pp. 512-524
Open Access | Times Cited: 4
An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials
Abdulrahman I. Alfayez, Jawaher M. Alfallaj, Mugahid A. Mobark, et al.
Current Diabetes Reviews (2023) Vol. 20, Iss. 2
Closed Access | Times Cited: 4
Abdulrahman I. Alfayez, Jawaher M. Alfallaj, Mugahid A. Mobark, et al.
Current Diabetes Reviews (2023) Vol. 20, Iss. 2
Closed Access | Times Cited: 4
The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
Takeshi Goya, Koji Imoto, Shigeki Tashiro, et al.
Gastroenterology Insights (2022) Vol. 13, Iss. 1, pp. 20-26
Open Access | Times Cited: 6
Takeshi Goya, Koji Imoto, Shigeki Tashiro, et al.
Gastroenterology Insights (2022) Vol. 13, Iss. 1, pp. 20-26
Open Access | Times Cited: 6
Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
Jaime Sanz‐Cánovas, Michele Ricci, Lidia Cobos-Palacios, et al.
Reviews in Cardiovascular Medicine (2023) Vol. 24, Iss. 2, pp. 36-36
Open Access | Times Cited: 3
Jaime Sanz‐Cánovas, Michele Ricci, Lidia Cobos-Palacios, et al.
Reviews in Cardiovascular Medicine (2023) Vol. 24, Iss. 2, pp. 36-36
Open Access | Times Cited: 3
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome (2023), Iss. 5, pp. 8-37
Open Access | Times Cited: 2
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome (2023), Iss. 5, pp. 8-37
Open Access | Times Cited: 2
Sodium‐glucose cotransporter 2 inhibitors: A comprehensive review from cells to bedside
Bahador Bagheri, Habib Yaribeygi, Erfan Taherifard, et al.
Fundamental and Clinical Pharmacology (2022) Vol. 37, Iss. 3, pp. 481-492
Open Access | Times Cited: 3
Bahador Bagheri, Habib Yaribeygi, Erfan Taherifard, et al.
Fundamental and Clinical Pharmacology (2022) Vol. 37, Iss. 3, pp. 481-492
Open Access | Times Cited: 3
I farmaci SGLT-2 inibitori: utilizzi nella pratica clinica oltre il diabete
Emanuele Varaldo, Alessandro Maria Berton, Daniela Cuboni, et al.
L Endocrinologo (2024)
Closed Access
Emanuele Varaldo, Alessandro Maria Berton, Daniela Cuboni, et al.
L Endocrinologo (2024)
Closed Access
Extraglycemic effects of NGLT2 inhibitors and effects on NAFLD as an effective way to improve cardiorenal prognosis in patients with type 2 diabetes
T. Yu. Demidova, M. Ya. Izmailova, Д. В. Скуридина
FOCUS Endocrinology (2023) Vol. 4, Iss. 3, pp. 62-68
Open Access
T. Yu. Demidova, M. Ya. Izmailova, Д. В. Скуридина
FOCUS Endocrinology (2023) Vol. 4, Iss. 3, pp. 62-68
Open Access
